OpenAI Is Planning To Fund A Brain-Computer Interface Startup To Rival Elon Musk's Neuralink- The Verge
ReutersAug 15, 2025 12:55 PM
Aug 15 (Reuters) -
OPENAI IS PLANNING TO FUND A BRAIN-COMPUTER INTERFACE STARTUP TO RIVAL ELON MUSK'S NEURALINK- THE VERGE
OPENAI'S ALTMAN INTERESTED IN BUYING CHROME IF THE US GOVERNMENT FORCES GOOGLE TO SELL IT- THE VERGE
OPENAI'S SAM ALTMAN SAYS WANTS TO RAISE TRILLIONS OF DOLLARS TO BUILD DATA CENTERS - THE VERGE
Source text: https://tinyurl.com/ycmbe356
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
Micron Technology Q4 FY2025 Earnings Preview: Leveraging DRAM Strength and Accelerating HBM Growth
TradingKey - Micron Technology, Inc. (NASDAQ: MU) will report Q4 FY2025 results after the market close on Tuesday, September 23, 2025, with the webcasted conference call scheduled for 4:30 PM EDT. As a leading global supplier of memory chips, including DRAM, NAND flash, and advanced memory like...TradingKey
4 hours ago
Costco FY2025 Q4 Earnings Preview: Decoding Growth Drivers and Market Bets Amid Sky-High Valuation
TradingKey - Since the release of Costco's fiscal 2025 third-quarter earnings report, its stock performance has slightly underperformed the S&P 500 index. After a significant year-to-date rally, the stock has entered a consolidation phase, exhibiting a contracting triangle pattern, reflecting...TradingKey
19 hours ago
Fed Rate Cuts: Will the Russell 2000 Outperform the S&P 500?
TradingKey - On 17 September, the Federal Reserve cut interest rates by 25 basis points, marking the official restart of the rate-cutting cycle. In theory, small-cap stocks, compared to large-cap stocks, benefit more from Fed rate cuts. This is because they are more reliant on external financing...TradingKey
21 hours ago
From Ozempic to Wegovy: Growth and Risks Behind Novo Nordisk’s Q2 Performance
TradingKey - Novo Nordisk achieved revenue of $11.67 billion in Q2 of the 2025 fiscal year, a 19% increase year-over-year, but it fell short of market expectations. Growth was primarily driven by strong performance in obesity care and rare diseases.TradingKey
Thu, Aug 7
ASML Q2 FY2025 Earnings Review: Strong Growth and High-NA EUV Breakthrough Shadowed by 2026 Uncertainty
ASML Holding N.V. (NASDAQ: ASML) released its Q2 FY2025 earnings on July 16, 2025, exceeding market expectations with robust net sales and net bookings, though the stock fell around 10% due to cautious guidance for 2026 amid geopolitical uncertainties.TradingKey
Mon, Jul 14
Tradingkey
